FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market shareThe high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.{}

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.https://www.cnbc.com/2026/03/19/fda-approves-high-dose-version-of-novo-nordisks-obesity-drug-wegovy.html